Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Completed
NewAmsterdam Pharma
Phase 2
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study
to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to
high-intensity statin therapy.
Randomized Study of Obicetrapib in Combination With Ezetimibe
Completed
NewAmsterdam Pharma
Phase 2
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in
participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of
obicetrapib and ezetimibe combination therapy.
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Not yet recruiting
NewAmsterdam Pharma
Phase 3
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in
participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD
to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and
maximally tolerated lipid-lowering therapy
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Not yet recruiting
NewAmsterdam Pharma
Phase 3
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in
participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately
controlled despite maximally tolerated lipid-lowering therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
